🇺🇸 FDA
Patent

US 7709002

Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes

granted A61KA61K39/00A61K40/11

Quick answer

US patent 7709002 (Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Apr 29 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue May 04 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 29 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K39/00, A61K40/11, A61K40/4253, A61K45/06